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Ökonomische Auswirkungen eines regionalen Managements
multiresistenter Erreger
Abstract
The increasing number of people who are colonized or infected with
multidrug-resistantbacteriaimposesahigheconomicburdenonsociety
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which includes the negative impact on health status as an intangible
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cost. An economic analysis leads to the conclusion that currently too
little is done to prevent or control infections. The reasons include insuf- University of Greifswald,
Greifswald, Germany ficient incentives for health care providers, a lack of reliable data on
both the prevalence and the effects of infection, and a lack of coordin-
ationamongthedifferentbranchesofthehealthcaresector.Aregional
management of multidrugresistant bacteria which does not focus on a
single branch but rather on the health care sector overall can achieve
a substantial reduction in the number of infected people and of the
associated economic cost for society.
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Zusammenfassung
DiezunehmendeAnzahlvonPersonen,diemitmultiresistentenErregern
kolonisiert oder infiziert sind, verursacht hohe volkswirtschaftliche
Kosten, zu denen auch die gesundheitlichen Beeinträchtigungen der
PatientenalsintangibleKostenrechnen.Esistzuvermuten,dassderzeit
in zu geringem Umfang Maßnahmen zur Infektionsprävention und zur
Eindämmung derartiger Erreger ergriffen werden. Zu den Ursachen
zählen unzureichende Anreize der Leistungserbringer, eine unbefriedi-
gende Datenlage sowie eine aufgrund der sektoralen Aufteilung des
Gesundheitswesens mangelnde Abstimmung der Leistungserbringer.
Diese Probleme können überwunden werden durch ein in geeigneter
WeiseausgestaltetesregionalesManagementmultiresistenterErreger,
das aufgrund seines Fokus auf die gesamte Versorgungskette die
Chance bietet, zu einer nennenswerten Senkung der Anzahl infizierter
PersonenundsomitzueinerdeutlichenVerringerungdervolkswirtschaft-
lichen Kosten multiresistenter Erreger beizutragen.
Schlüsselwörter: multiresistente Erreger, volkswirtschaftliche Kosten,
regionales Management
Introduction
Over the last few years, the number of people infected
with multidrug-resistant bacteria has been rising in a
numberofcountries,amongthemGermany.Asacharac-
teristic feature, multidrug-resistant bacteria are not sus-
ceptible to several antibiotics. This inhibits the efficacy
of antibiotic treatment, with serious consequences for
the health of infected individuals, the utilization of re-
sources in the health care sector and the availability of
resources in the economy in general. Following an infec-
tionwithmultidrug-resistantbacteria,anumberofeffects
may arise, each representing an economic cost: First, an
individual will suffer from the risk of severe impairment
of her health, including premature death. Next, appropri-
ate treatment will take more time to produce the desired
healthoutcomeorwillrequiremoreresourceswhichmust
be diverted from other uses in the health care sector. In
addition, the economy will incur losses in productivity
whenever infected individuals belong to the workforce.
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infected individuals may spread multidrug-resistant bac-
teria,thusinflictingharmonotherindividualsandincreas-
ing the economic cost to society.
A first objective of the present contribution is to work out
in more detail the economic effects which an infection or
acolonizationwithmultidrug-resistantbacteriamaybring
about. Building on this account, it will be argued that the
statusquoisinefficient.Next,anapproachwillbeoutlined
which can be used to determine whether strategies to
prevent or to reduce infections with multidrug-resistant
bacteria provide a net benefit to society. In order to be
able to implement a strategy that has been shown to be
advantageous in this sense, it is salient to provide appro-
priate incentives to the main actors involved. In essence,
both objectives require a regional management of mul-
tidrug-resistantbacteria.Bytakingintoaccounttheentire
health care sector within a region, this type of manage-
ment can be trusted to improve on the current situation.
Method
Inordertocarryoutthetasksoutlinedabove,itisimport-
anttobeclearabouthowtoassessthecostsandbenefits
associatedwithstrategiestopreventorreduceinfections
with multiresistant bacteria. Furthermore, the range of
effects which need to be taken into account will depend
ontheperspectiveoftheanalysis.Morespecifically,while
the (in-)efficiency of the status quo or of an intervention
can only be evaluated from the perspective of society,
the issue of (in-)appropriate incentives must be judged
from the individual perspective.
First,itishelpfultodistinguishthreetypesofcosts.Direct
costsrepresentthemonetaryvalueofresourceutilization
that takes place due to the production and consumption
of health care. Apart from the cost of health care itself,
thisalsoincludesanycostincurredbythepatientinorder
to receive care, e.g., travel costs. The next type is given
byindirectcostswhichcovertheproductivitylosses,also
valued in monetary units, due to illness or premature
death. Finally, intangible costs capture the loss in utility
or welfare for the patient which results from a reduction
inherhealthstatus(includingdeath).Incomparisonwith
the other two types, intangible costs are more difficult to
measure because it is necessary to develop a valuation
from scratch. Intangible costs can be measured either in
monetaryunits(i.e.,aswillingness-to-pay)orinotherunits
such as quality-adjusted life years (QALYs).
Next, strategies which aim to prevent infections with
multidrug-resistantbacteriaortocontroltheirimpactwill
usuallyinvolveareductionintheassociatedcosts.Relying
on a similar categorization as on the cost side, these be-
nefits may turn up either as direct benefits, or as indirect
benefits, or finally as intangible benefits. Whereas direct
benefits (or indirect benefits) accrue as reductions in
direct costs (or indirect costs), intangible benefits arise
from improvements in health status or an extension of
length of life.
Fromtheindividualperspectiveofaneconomicunitsuch
as, e.g., a physician, an insurer, or a patient, it makes
sense to take into account only those costs and benefits
which accrue to the unit itself. Thus, a decision is individ-
ually rational if it maximizes benefits over costs for the
unit,therebyreapingthegreatestnetbenefit.Incontrast,
thesocietalperspectivetakesintoaccountthecostsand
benefitsofalldecisionunits.Hence,adecisionisrational
from the perspective of society, or efficient for short, if it
maximizes the net benefit that accrues to society. Other-
wise, it is inefficient and it is at least possible to make
everyone better off by moving to an efficient decision.
It is important to realize that both the perspectives are
necessary to explain why inefficient decisions involving
a waste of resources are taken and how they can be im-
proved upon. According to a basic assumption that will
also be imposed below, economic units always act indi-
vidually rational, i.e., they always maximize their own net
benefit.Simplethoughitis,thisassumptionnevertheless
can be quite helpful in explaining inefficient decisions.
More precisely, such decisions are likely to occur
whenever the associated costs and benefits do not fall
exclusively on the unit who takes them.
E.g., patients infected with multidrug-resistant bacteria
arelikelytoreceiveinefficienthealthcareiftheproviders
have no incentive to take into account all the costs and
benefits associated with the treatment they provide. Ap-
plying the societal perspective provides the only way to
identify those strategies to prevent or control infections
that are efficient. In order to promote their implementa-
tion, it is essential to modify the incentives which the
providers of health care face such that applying an effi-
cient strategy is in their own interest, i.e., becomes indi-
vidually rational. As claimed above, this demonstrates
that both the societal perspective and the individual
perspectives of the relevant players must be taken into
account in order to arrive at an efficient provision of
health care to patients infected with multidrug-resistant
bacteria.
Results
Individuals who are colonized with multidrug-resistant
bacteria but not yet infected usually do not suffer from
any immediate consequences. However, there are sub-
stantial risks involving serious medical problems and
economic costs, both for the individuals themselves as
well as for other individuals who get in touch with them.
First,thereistheriskofdevelopinganinfection,imposing
directandintangiblecostsandpossiblyalsoindirectcosts
asoutlinedabove.Theavailablestudies,usuallyfocusing
on one type of bacteria and on a single disease, clearly
demonstrate a considerable increase in length-of-stay
and in direct hospital costs [1], [2], [3], [4], [5]. Even
thoughthereductionsinhealthstatusduetoaninfection
with multidrug-resistant bacteria are less well docu-
mented, the associated rise in mortality indicates that
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At the same time, individuals colonized with multidrug-
resistant bacteria put other individuals at risk because
their presence increases the probability that further col-
onization will take place. Therefore, the cost effects de-
scribed above may also occur among other individuals.
An analysis of the costs of multidrug-resistant bacteria
from the societal perspective must take these costs into
account as well. Economically speaking, they represent
external costs because the colonization of one individual
may exert a negative impact upon the health status of
other individuals [9], [10].
In fact, the external effects may reach very far, both with
respecttothenumberofindividual’sconcernedandover
time. Consider the use of antibiotics: Even with proper
use in treatment, eventually resistant bacteria will turn
up.However,antibioticmisuseonthepartofeitherhealth
care providers or patients substantially accelerates the
evolution of resistant strains. Thus, a flawed treatment
of patients today imposes a cost on future patients. In
economic terms, efficacy of antibiotic treatment can be
viewed as a common social good which, due to wrong
incentives for the major players in the health care sector,
suffers from the tragedy of the commons [11].
In order to move towards a solution of the current prob-
lems with multidrug-resistant bacteria, it is necessary to
identify strategies for improving the provision of health
care. In a further step, care must be taken to make sure
thatpromisingstrategieswillalsobeimplementedbythe
relevant actors. Applying both steps in a systematic
manner regularly and based on appropriate empirical
data to check available strategies to prevent or control
infections, one obtains a management of multidrug-re-
sistant bacteria. Given the problems of the status quo as
outlined above, a change from simply dealing with mul-
tidrug-resistantbacteriaadhoctoapropermanagement
can be expected to result in a substantial reduction in
the associated costs for society.
As a first step, it is necessary to evaluate the costs and
benefits to society arising from strategies to prevent in-
fectionswithmultidrug-resistantbacteria.Strategiesthat
confer a net benefit to society improve on the current
provision of health care and contribute to attaining the
goal of an efficient management. Observe that the term
strategy is defined in a narrow sense: In particular, it
refers to a specific group of patients receiving care from
aspecificproviderataspecificplace.Thus,ifthebenefits
of,e.g.,ascreeningstrategyexceedtheassociatedcosts,
it is nevertheless possible that a further modification, for
examplebyfocusingonadifferentgroupofpatients,may
provide an ever higher net benefit to society.
There are good reasons to tackle these tasks within a
regionalmanagementofmultidrug-resistantbacteria.As
its name suggests, a regional management has a clear
focus on a specific region but implies no further restric-
tions otherwise. Thus, it represents a comprehensive
approach which is not confined to a single branch of the
healthcaresystem.Furthermore,inviewoftheproblems
outlined above it seems necessary to adopt a regional
managementbecausesuchanapproachoffersaunique
opportunity to apply the perspective of society to
strategies to prevent or control infections with multidrug-
resistant bacteria. This includes the setup and the con-
tinuousmaintenanceofadatabaserelatingtomultidrug-
resistant bacteria in order to record the prevalences of
colonizedindividualsorinfectedpatientsaswellasother
relevant data. A major objective would be to take into
account the entire process of the development and also
the spread of colonization and infections with multidrug-
resistant bacteria. In some contrast to the prevailing ap-
proach with its focus on hospitals and on the control of
infections, a regional management offers the prospect
to recognize both the contribution of other health care
providers and of strategies to prevent infections in order
to deal with infections with multidrug-resistant bacteria
in a manner that provides a maximum net benefit to so-
ciety.
Discussion
At present, a major problem is that appropriate data on
thecostsofcolonizationwithmultidrug-resistantbacteria
are not available. To be sure, attempts to obtain repre-
sentative data which are not confined to hospitals have
intensified recently. Nevertheless, there are still no or at
least no systematic data on some of the cost effects ex-
plained above. Referring to infections with multidrug-
resistant bacteria, this is true for the direct costs outside
of hospitals as well as for the intangible costs due to a
reduction in length of life or a deterioration of health
status. In addition, there is no evidence on the probabil-
itieswithwhichcolonizedindividualsdevelopaninfection
or cause other individuals either to be colonized or in-
fectedwithmultidrug-resistantbacteria.Thesedatawould
need to be collected with respect to the type of bacteria
(pathogen) and possibly also with respect to individual
attributessuchas,e.g.,ageorprevailingchronicdiseases.
Notethatthelackofdataonsomeimportantcosteffects
also has further implications. Since the benefits of
strategies to prevent or control infections arise primarily
as reductions in the direct, indirect or intangible costs of
multidrug-resistant bacteria, the full benefits to society
are not known either. More specifically, there is a lack of
data on the impact of efforts to prevent infections, and
also on the valuation of the corresponding health effects
by the affected individuals.
In order to explain the present scale of infections with
multidrug-resistant bacteria in Germany, it is necessary
to investigate the incentives of health care providers to
employ strategies to prevent or control infections. Con-
sider a health care provider who applies a screening test
to patients deemed at risk such that patients will be
isolated until the result becomes available and will be
sanified if the test yields a positive result. In many in-
stances, for the provider this means incurring a certain
cost with the prospect of only a small expected benefit:
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nil) and/or the strategy may not generate enough cost
savings for the provider. The latter reason applies, e.g.,
to ambulatory physicians because the higher cost of
treatment due to an infection will occur primarily in hos-
pitals.Furthermore,theadditionalbenefitsduetoaverted
infections of other individuals will have no direct effect
on the provider under consideration either. A similar
statement applies to the careful and cautious therapy
with antibiotics which may also contain the development
andthespreadofmultidrug-resistantbacteria:Again,the
cost falls primarily upon the prescribing physician
whereas the benefit turns up elsewhere in society.
Even though it is not possible currently to describe the
economicimpactofcolonizationwithmultidrug-resistant
bacteria in full, the lack of sufficiently strong incentives
forhealthcareproviderscansafelybetakentoimplythat
too little effort is devoted to the prevention or the control
ofinfections.Asagauge,considerthecostsandbenefits
to society of strategies to prevent or control infections
withmultidrug-resistantbacteria:Asarguedabove,health
care providers implementing such strategies will usually
reaponlypartoftheassociatedbenefitwhilebearingthe
full cost. Therefore, the incentives facing health care
providersaretooweaktoinducethemtoprovideefficient
care with respect to the protection from infections with
multidrug-resistant bacteria. In turn, this implies that,
from the perspective of society, there will be too many
infections imposing an overall cost that is unnecessarily
high.
Ifastrategytopreventinfectionswithmultidrug-resistant
bacteria conferring a net benefit to society has been
identified, the next task is to make sure that it will be
implemented.Inessence,thismeanssettingappropriate
incentives: The net benefit to society needs to be distrib-
uted among the relevant actors in a manner such that it
isindividuallyrationalforeverybodytoapplythestrategy.
More specifically, this implies an appropriate remunera-
tion of health care providers, covering at least their own
cost due to the effort to prevent or control infections with
multidrug-resistantbacteria.Moreover,itmaymakesense
to promote the cooperation among different sectors of
the health care system, given that multidrug-resistant
bacteriaturnupnotonlyinhospitalsbutalsoinambulat-
ory care or in nursing homes.
Applying a regional management in a suitable manner
also offers the prospect of overcoming the tragedy of the
commons problem that besets the current approach to
multidrug-resistant bacteria. By implementing the per-
spective of society in an entire region, it will be possible
to take into account most of the substantial cost effects
that are now external. Improving surveillance as well as
providing reliable information on the appropriate use of
antibiotics may help to improve the efficacy of treatment
for future patients. In this sense, a successful regional
management may also contribute to save costs in the
health care sector and to improve the health of patients
in the future.
Conclusion
The current provision of health care to individuals who
arecolonizedorinfectedwithmultidrug-resistantbacteria
suffers from a number of shortcomings due to, e.g., a
lack of data and inappropriate incentives for providers.
Implementing suitable strategies to control or prevent
infections offers the prospect of reducing the costs asso-
ciated with multidrug-resistant bacteria substantially,
either by improving the health status of patients or by
easing the financial burden on the health care system.
For several reasons, a regional management represents
anapproachthatcanbetrustedtoimproveonthestatus
quo and to reap substantial net benefits for society by
better dealing with the problems caused by multidrug-
resistant bacteria.
It is true that building up and maintaining a regional
management of multidrug-resistant bacteria will involve
a considerable cost. However, given the high costs of the
statusquowhichwillcontinuetoriseunlessprecautionary
measures are taken, this cost will be more than offset by
thebenefitsthatcanbereapedbyimplementingefficient
strategies to prevent or control infections. A regional
management of multidrug-resistant bacteria represents
the first step towards a better integration of the health
care system. If this step is taken successfully, it may also
act as a role model for dealing with other problems in the
provisionofhealthcare.Atanyrate,thepotentialbenefits
appeartobesufficientlyhightomorethanjustifyembark-
ing on this first step.
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